Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with ifosfamide combinations in malignant lymphomas.

F Cabanillas1

  • 1M.D. Anderson Cancer Center, Department of Hematology, Houston, TX 77030.

Seminars in Oncology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curability Potential of Low-Grade Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2007
Same author

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

The MIME regimen showed a 60% response rate for aggressive lymphomas, while a novel front-line approach achieved an 81% complete response rate and 62% 10-year survival, demonstrating ifosfamide

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ifosfamide-containing regimens are used in lymphoma treatment.
  • Salvage and front-line chemotherapy strategies are being evaluated.

Purpose of the Study:

  • To evaluate the efficacy of the MIME (methyl-glyoxal-bis-guanylhydrazone, ifosfamide, methotrexate, etoposide) salvage regimen.
  • To assess a novel front-line chemotherapy regimen incorporating ifosfamide, designed to maximize complete response (CR) rates.

Main Methods:

  • The MIME regimen was administered to 208 patients with aggressive lymphomas.
  • A front-line regimen involved sequential chemotherapy (CHOP, HOAP-Bleo, IMVP-16) based on response after every three courses.

Main Results:

  • The MIME regimen achieved a 60% overall response rate and 24% CR rate, with 25% of CRs achieving sustained remissions >2 years.

Related Experiment Videos

  • Front-line therapy resulted in an 81% CR rate and 62% 10-year survival.
  • Long-term survival for intermediate-grade lymphoma patients was 15%.

    • Conclusions:

    • Ifosfamide-containing regimens, including MIME and the novel front-line approach, show significant activity in lymphoma treatment.
    • The front-line strategy demonstrated a high CR rate and favorable long-term survival, comparable to other third-generation regimens.